Murine L1210 and P388 Leukemias

作者: William R. Waud

DOI: 10.1007/978-1-60761-968-0_2

关键词: Clinical trialP388 leukemiaAnticancer drugDrug resistanceCancer researchHuman leukemiaMedicineCombination chemotherapyHuman cancerLeukemia

摘要: L1210 and P388 leukemia models have been extensively used over the last 50 years. The are rapid, reproducible, relatively inexpensive (in comparison to human tumor xenograft transgenic models). However, as with any experimental animal model, there limitations. Neither is a satisfactory model for either cancer in general or particular. Despite limitations of murine models, these useful making progress anticancer drug development, development number therapeutic principles, understanding biologic behavior host. These still today conducting detailed evaluations new candidate drugs (e.g., schedule dependency, route administration formulation comparison, analog combination chemotherapy). greatest utility leukemias derived from drug-resistant sublines crossresistance collateral sensitivity. Crossresistance data, coupled knowledge resistance mechanisms operative leukemias, may yield insights into action agents. Similarly, various agents, leukemias. Furthermore, data identify potentially guides patient selection clinical trials antitumor drugs.

参考文章(24)
William R. Waud, Therapeutic Resistance in Leukemia Humana Press. pp. 137- 150 ,(2006) , 10.1007/978-1-59745-035-5_7
Beverly A. Teicher, Drug resistance in oncology Marcel Dekker. ,(1993)
M. Moore, Brian W. Fox, Basis for cancer therapy Pergamon. ,(1979)
Montgomery Ja, Johnston Tp, Schabel Fm, Laster Wr, Skipper He, McCALEB Gs, Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Research. ,vol. 23, pp. 725- 733 ,(1963)
D Selwood, Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval British Journal of Cancer. ,vol. 91, pp. 1000- 1000 ,(2004) , 10.1038/SJ.BJC.6602070
Daniel P. Griswold, Steadman D. Harrison, Tumor models in drug development. Cancer and Metastasis Reviews. ,vol. 10, pp. 255- 261 ,(1991) , 10.1007/BF00050796
E. M. Nelson, K. M. Tewey, L. F. Liu, Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide Proceedings of the National Academy of Sciences of the United States of America. ,vol. 81, pp. 1361- 1365 ,(1984) , 10.1073/PNAS.81.5.1361
Anthony D. Ho, Eva Seither, David D. F. Ma, H. Grant Prentice, Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells. British Journal of Haematology. ,vol. 65, pp. 51- 55 ,(1987) , 10.1111/J.1365-2141.1987.TB06134.X
F.M. Schabel, D.P. Griswold, W.R. Laster, T.H. Corbett, H.H. Lloyd, Quantitative evaluation of anticancer agent activity in experimental animals Pharmacology & Therapeutics. Part A: Chemotherapy, Toxicology and Metabolic Inhibitors. ,vol. 1, pp. 411- 435 ,(1977) , 10.1016/0362-5478(77)90004-3